Yungjin Pharm영진약품

Yungjin Pharm's shares have fallen sharply over the past year and the company is loss-making on a trailing basis as of H1 2026.

Yungjin Pharm is a Korean prescription drug maker with a focus on antibiotics, nutrition products and other prescription medicines, selling mainly in South Korea with some exports, mostly to Japan. Trailing twelve-month revenue is about ₩253B, but operating and net losses have pushed the company into negative territory, and borrowings of ₩54B are high relative to cash of ₩3.6B. The share price closed at ₩945, near its 52-week low of ₩945 and well below its 52-week high of ₩2,320.

What stands out

• Trailing revenue of ₩253B is roughly flat with 2025's ₩254B, but the trailing operating loss of ₩4.3B contrasts with a 2025 operating profit of ₩3.4B.
• 2025 net loss was ₩0.2B and trailing net loss is ₩6.3B, so profitability has weakened in 2026.
• Liabilities are 163.9% of equity and free cash flow is negative at ₩6.4B, while cash is only ₩3.6B against ₩54B of borrowings.
• The share price is down 53.1% over one year and 22.5% over three months, and foreign ownership fell from 2.9% to 2.1% over 60 days.
• Recent filings include amended major sales or supply contracts, a lawsuit filed or ruled, and a half-year report for June 2026; the data does not describe their financial impact.

What to watch

• The next quarterly or annual results, to see whether operating income returns to profit given the current trailing loss.
• Developments in the lawsuit and the amended supply contracts, whose terms and size are not included in the data.
• Funding pressure from high borrowings and negative free cash flow; the data does not show any dividend, and the valuation P/E is not meaningful because earnings are negative.